
Denali Therapeutics (DNLI) Stock Forecast & Price Target
Denali Therapeutics (DNLI) Analyst Ratings
Bulls say
Denali Therapeutics Inc demonstrates a promising financial outlook, with revenue projections for its TIVI product expected to rise from $8 million in 2026 to $433 million by FY30. The company's management has expressed confidence in the potential for TIVI to receive accelerated approval for MPS II by the specified PDUFA date, which could significantly enhance the company's commercial prospects. Additionally, the anticipated advantages of the DNL310 product over the current competitive offerings further solidify the positive sentiment surrounding Denali's pipeline developments.
Bears say
Denali Therapeutics is projected to generate significantly lower revenues, estimating only $8 million in 2026, compared to the consensus estimate of $44 million, indicating potential concerns regarding market demand and product viability. The company's capacity to advance its development programs is jeopardized by a failure to raise capital, which may hinder timely completion of critical projects. Additional risks include competitive pressures from other firms, potential regulatory delays, and challenges related to manufacturing and scaling operations, all of which could negatively impact the company's financial performance and stock outlook.
This aggregate rating is based on analysts' research of Denali Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Denali Therapeutics (DNLI) Analyst Forecast & Price Prediction
Start investing in Denali Therapeutics (DNLI)
Order type
Buy in
Order amount
Est. shares
0 shares